Provided by Tiger Trade Technology Pte. Ltd.

Citius Pharmaceuticals, Inc.

0.5748
-0.0254-4.23%
Volume:320.61K
Turnover:185.52K
Market Cap:15.78M
PE:-0.27
High:0.6100
Open:0.6100
Low:0.5700
Close:0.6002
52wk High:2.19
52wk Low:0.4687
Shares:27.45M
Float Shares:26.96M
Volume Ratio:0.32
T/O Rate:1.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1219
EPS(LYR):-3.3830
ROE:-81.09%
ROA:-26.57%
PB:0.24
PE(LYR):-0.17

Loading ...

Company Profile

Company Name:
Citius Pharmaceuticals, Inc.
Exchange:
NASDAQ
Establishment Date:
2007
Employees:
23
Office Location:
11 Commerce Drive,First Floor,Cranford,New Jersey,United States
Zip Code:
07016
Fax:
- -
Introduction:
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Directors

Name
Position
Leonard Mazur
Chief Executive Officer,Director,Executive Chairman and Secretary
Myron Holubiak
Director and Executive Vice-Chairman
Carol Webb
Independent Director
Dennis M. McGrath
Independent Director
Eugene Holuka
Independent Director
Robert Smith
Independent Director
Suren Dutia
Independent Director

Shareholders

Name
Position
Leonard Mazur
Chief Executive Officer,Director,Executive Chairman and Secretary
Jaime Bartushak
Chief Financial Officer and Chief Business Officer
Myron Czuczman
Chief Medical Officer and Executive Vice President
Myron Holubiak
Director and Executive Vice-Chairman